Estrella Immunopharma announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the company dosed the first patient in its Phase I/II clinical trial for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. Zhang’s appointment increases the size of Estrella’s Board from five to six directors. Cheng Liu, Estrella’s CEO and previous Chairman, will continue to serve as a director on the Board.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue